Pamela Samson1, Aalok Patel1, Traves D Crabtree1, Daniel Morgensztern2, Cliff G Robinson3, Graham A Colditz4, Saiama Waqar2, Daniel Kreisel1, A Sasha Krupnick1, G Alexander Patterson1, Stephen Broderick1, Bryan F Meyers1, Varun Puri5. 1. Division of Cardiothoracic Surgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri. 2. Division of Medical Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri. 3. Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri. 4. Institute for Public Health, Washington University School of Medicine in St. Louis, St. Louis, Missouri. 5. Division of Cardiothoracic Surgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri. Electronic address: puriv@wudosis.wustl.edu.
Abstract
BACKGROUND: Improved survival of patients with early-stage non-small cell lung cancer (NSCLC) undergoing resection at high-volume centers has been reported. However, the effect of institution is unclear in stage IIIA NSCLC, where a variety of neoadjuvant and adjuvant therapies are used. METHODS: Treatment and outcomes data of clinical stage IIIA NSCLC patients undergoing resection as part of multimodality therapy was obtained from the National Cancer Database. Multivariable regression models were fitted to evaluate variables influencing 30-day mortality and overall survival. RESULTS: From 1998 to 2010, 11,492 clinical stage IIIA patients underwent resection at community centers, and 7,743 patients received resection at academic centers. Academic center patients were more likely to be younger, female, non-Caucasian, have a lower Charlson-Deyo comorbidity score, and to receive neoadjuvant chemotherapy (49.6% vs 40.6%; all p < 0.001). Higher 30-day mortality was associated with increasing age, male gender, preoperative radiotherapy, and pneumonectomy. Patients undergoing operations at academic centers experienced lower 30-day mortality (3.3% vs 4.5%; odds ratio, 0.75; 95% confidence interval [CI], 0.60 to 0.93; p < 0.001). Decreased long-term survival was associated with increasing age, male gender, higher Charlson-Deyo comorbidity score, and larger tumors. Neoadjuvant chemotherapy (hazard ratio, 0.66; 95% CI, 0.62 to 0.70), surgical intervention at an academic center (hazard ratio, 0.92; 95% CI, 0.88 to 0.97), and lobectomy (hazard ratio, 0.72; 95% CI, 0.67 to 0.77) were associated with improved overall survival. CONCLUSIONS: Stage IIIA NSCLC patients undergoing resection at academic centers had lower 30-day mortality and increased overall survival compared with patients treated at community centers, possibly due to higher patient volume and an increased rate of neoadjuvant chemotherapy.
BACKGROUND: Improved survival of patients with early-stage non-small cell lung cancer (NSCLC) undergoing resection at high-volume centers has been reported. However, the effect of institution is unclear in stage IIIA NSCLC, where a variety of neoadjuvant and adjuvant therapies are used. METHODS: Treatment and outcomes data of clinical stage IIIA NSCLCpatients undergoing resection as part of multimodality therapy was obtained from the National Cancer Database. Multivariable regression models were fitted to evaluate variables influencing 30-day mortality and overall survival. RESULTS: From 1998 to 2010, 11,492 clinical stage IIIA patients underwent resection at community centers, and 7,743 patients received resection at academic centers. Academic center patients were more likely to be younger, female, non-Caucasian, have a lower Charlson-Deyo comorbidity score, and to receive neoadjuvant chemotherapy (49.6% vs 40.6%; all p < 0.001). Higher 30-day mortality was associated with increasing age, male gender, preoperative radiotherapy, and pneumonectomy. Patients undergoing operations at academic centers experienced lower 30-day mortality (3.3% vs 4.5%; odds ratio, 0.75; 95% confidence interval [CI], 0.60 to 0.93; p < 0.001). Decreased long-term survival was associated with increasing age, male gender, higher Charlson-Deyo comorbidity score, and larger tumors. Neoadjuvant chemotherapy (hazard ratio, 0.66; 95% CI, 0.62 to 0.70), surgical intervention at an academic center (hazard ratio, 0.92; 95% CI, 0.88 to 0.97), and lobectomy (hazard ratio, 0.72; 95% CI, 0.67 to 0.77) were associated with improved overall survival. CONCLUSIONS: Stage IIIA NSCLCpatients undergoing resection at academic centers had lower 30-day mortality and increased overall survival compared with patients treated at community centers, possibly due to higher patient volume and an increased rate of neoadjuvant chemotherapy.
Authors: David S Ettinger; Wallace Akerley; Gerold Bepler; Matthew G Blum; Andrew Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Apar Kishor P Ganti; Ramaswamy Govindan; Frederic W Grannis; Thierry Jahan; Mohammad Jahanzeb; David H Johnson; Anne Kessinger; Ritsuko Komaki; Feng-Ming Kong; Mark G Kris; Lee M Krug; Quynh-Thu Le; Inga T Lennes; Renato Martins; Janis O'Malley; Raymond U Osarogiagbon; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; George R Simon; Scott J Swanson; Douglas E Wood; Stephen C Yang Journal: J Natl Compr Canc Netw Date: 2010-07 Impact factor: 11.908
Authors: Subroto Paul; Farooq Mirza; Jeffrey L Port; Paul C Lee; Brendon M Stiles; Amanda L Kansler; Nasser K Altorki Journal: J Thorac Cardiovasc Surg Date: 2010-11-18 Impact factor: 5.209
Authors: M W J M Wouters; S Siesling; M L Jansen-Landheer; M A G Elferink; J Belderbos; J W Coebergh; F M N H Schramel Journal: Eur J Surg Oncol Date: 2010-07-03 Impact factor: 4.424
Authors: Richard K Freeman; Jaclyn M Van Woerkom; Amy Vyverberg; Anthony J Ascioti Journal: Eur J Cardiothorac Surg Date: 2010-03-04 Impact factor: 4.191
Authors: Farhood Farjah; David R Flum; Thomas K Varghese; Rebecca Gaston Symons; Douglas E Wood Journal: Ann Thorac Surg Date: 2009-04 Impact factor: 4.330
Authors: Richard J Cassidy; Xinyan Zhang; Jeffrey M Switchenko; Pretesh R Patel; Joseph W Shelton; Sibo Tian; Ronica H Nanda; Conor E Steuer; Rathi N Pillai; Taofeek K Owonikoko; Suresh S Ramalingam; Felix G Fernandez; Seth D Force; Theresa W Gillespie; Walter J Curran; Kristin A Higgins Journal: Cancer Date: 2018-01-08 Impact factor: 6.860
Authors: Sara L Zettervall; Tammy Ju; Jeremy L Holzmacher; Lisbi Rivas; Paul P Lin; Khashayar Vaziri Journal: J Gastrointest Surg Date: 2018-03-02 Impact factor: 3.452
Authors: Yanyan Lou; Bhagirathbhai Dholaria; Aixa Soyano; David Hodge; Jordan Cochuyt; Rami Manochakian; Stephen J Ko; Mathew Thomas; Margaret M Johnson; Neal M Patel; Robert C Miller; Alex A Adjei; Sikander Ailawadhi Journal: Cancer Med Date: 2018-09-02 Impact factor: 4.452
Authors: Zaid Muslim; Syed S Razi; Kostantinos Poulikidis; M Jawad Latif; Joanna F Weber; Cliff P Connery; Faiz Y Bhora Journal: JTCVS Open Date: 2022-07-11